Open AccessClinical value of seven autoantibodies combined detection in the diagnosis of lung cancer
Author(s) -
Mu Yinyu,
Xie Fuyi,
Sun Tingting
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23349
Subject(s) - autoantibody , lung cancer , medicine , receiver operating characteristic , gastroenterology , pathological , cancer , lung , oncology , pathology , immunology , antibody
Background To analyze the clinical value of seven autoantibodies (p53, PGP9.5, SOX2, GAGE7, GBU4‐5, MAGE A1 and CAGE) in lung cancer patients. Methods ELISA was used to determine serum levels of seven autoantibodies in 177 patients with lung cancer, 201 healthy persons, and 210 patients with benign pulmonary diseases. Positive rates of 7 autoantibodies were analyzed; receiver operating characteristic (ROC) curves were drawn to analyze their diagnostic efficiency in lung cancer and to compare the positive rate of seven kinds of autoantibody combined detection of lung cancer patients with different clinicopathological features. Results The positive rate of seven autoantibodies in all subjects was 13.44%. The positive rate of seven autoantibodies in lung cancer was 25.42%. The positive rate of the combined detection of seven autoantibodies in the lung cancer group was significantly higher than that in healthy control group ( χ 2 = 19.76, P < .001) and benign lung disease group ( χ 2 = 21.44, P < .001). Sensitivity, specificity, and AUC ROC of the seven autoantibodies were 25.42%, 91.75%, and 0.683, respectively. Sensitivity and AUC ROC were higher than those of the single autoantibody detection. Positive rates of seven autoantibodies in different pathological types and clinical stages of lung cancer patients were significantly different ( P < .05). Conclusions The combined detection of 7 autoantibodies in lung cancer has some clinical value for the auxiliary diagnosis of lung cancer.